Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?

References

• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.
   PubMed Web of Science ®Google Scholar
• Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: An overview. J Gastroenterol Hepatol. 2002;17:1136–42.
   PubMedGoogle Scholar
• Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis. 2008;200:1–12.
   PubMed Web of Science ®Google Scholar
• Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, . Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007;18:184–95.
   PubMed Web of Science ®Google Scholar
• Lucero D, Zago V, López GI, Graffigna M, Fainboim H, Miksztowicz V, . Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta. 2011;412:143–7.
   PubMed Web of Science ®Google Scholar
• Chiang CH, Huang CC, Chan WL, Chen JW, Leu HB. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem. 2010;43:1399–404.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Rodella S. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–21.
   PubMed Web of Science ®Google Scholar
• Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–40.
   PubMed Web of Science ®Google Scholar
• Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203:581–6.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, . Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–42.
   PubMed Web of Science ®Google Scholar
• Meier U, Gressner A. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem. 2004;50:1511–25.
   PubMed Web of Science ®Google Scholar
• Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, . Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98:361–9.
   PubMedGoogle Scholar
• Matafome P, Nunes E, Louro T, Amaral C, Crisóstomo J, Rodrigues L, . A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:241–51.
   PubMed Web of Science ®Google Scholar
• Chrysohoou C, Pitsavos C, Skoumas J, Masoura C. The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population, the ATTICA Study. Int J Cardiol. 2006;122:29–33.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010 Nov 2 (Epub ahead of print).
   PubMedGoogle Scholar
• ; Cholesterol Treatment Trialists’ (CTT) CollaborationBaigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, ; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, ; for the JUPITER Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82.
   PubMed Web of Science ®Google Scholar
• Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;23:1643–7.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, De Michieli F, Biroli G, Fagà E, Pagano G, . Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Ann Med. 2008;40:383–94.
   Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, . Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22:873–83.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198–202.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, . Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism. 2005;54:1065–74.
   PubMed Web of Science ®Google Scholar
• Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, . Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol. 2004; 23:131–4.
   PubMedGoogle Scholar
• Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008;14:6395–400.
   PubMed Web of Science ®Google Scholar
• Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, . Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. J Indian Med Assoc. 2008;106:464–7.
   Google Scholar
• Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatin pre-treatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2010;72:566–8.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Koniari K, Antoniades C, Papageorgiou N, Miliou A, Noutsou M, . Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. Int J Cardiol. 2009 Dec 24. (Epub ahead of print).
   Google Scholar
• Matafome P, Monteiro P, Nunes E, Louro T, Amaral C, Moedas AR, . Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia. Pharmacol Res. 2008;58:208–14.
   Google Scholar
• Vuppalanchi R, Chalasani N. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Selected practical issues in their evaluation and management. Hepatology. 2009;49:306–17.
   PubMed Web of Science ®Google Scholar
• Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, . The effects of discontinuing pioglitazone in pateints with nonalcoholic steatohepatitis. Hepatology. 2007;46:424–9.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, . Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100–10.
   PubMed Web of Science ®Google Scholar
• Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, . Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713–8.
   PubMed Web of Science ®Google Scholar
• Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16:39–46.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, . Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation. 2005;111:2518–24.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, ; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004;18:781–8.
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for non-alcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther. 2006;24:698–9.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, ; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916–22.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, . Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–28.
   PubMed Web of Science ®Google Scholar
• Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol. 2011;9:62–86.
   PubMed Web of Science ®Google Scholar
• Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, . Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101–7.
   PubMed Web of Science ®Google Scholar
• Park H, Hasegawa G, Shima T, Fukui M, Nakamura N, Yamaguchi K, . The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. Clin Chim Acta. 2010;411:1735–40.
   Google Scholar
• Ahmed MH, Byrne CD. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discov Today. 2010;15:590–5.
   Google Scholar
• Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, . Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res. 2010;40:613–21.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother. 2010;11:1965–70.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes? Curr Pharm Des. 2010;16:3939–47.
   Google Scholar
• Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265–78.
   PubMed Web of Science ®Google Scholar
• Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2003;4:611–23.
   PubMed Web of Science ®Google Scholar
• Toutouzas K, Drakopoulou M, Skoumas I, Stefanadis C. Advancing therapy for hypercholesterolemia. Expert Opin Pharmacother. 2010;11:1659–72.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, . The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–34.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant. 2007;22:963–4.
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis. 2006;47:561.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin. 2003;19:615–7.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, ; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–9.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–16.
   PubMed Web of Science ®Google Scholar